Prognostic Value of a Composite Score Incorporating Baseline [18F]FDG PET/CT and [68Ga]Ga-PSMA-11 PET/CT When Screening for [177Lu]Lu-PSMA Treatment Eligibility (PROFILE Study) [0.03%]
基线[18F]FDG-PET/CT和[68Ga]Ga-PSMA-11 PET/CT综合评分在筛选符合[177Lu]Lu-PSMA治疗条件中的预后价值(PROFILE研究)
Adrien Jougla,Prescillia Nunes,Anne-Laure Giraudet et al.
Adrien Jougla et al.
We investigated the prognostic value of baseline [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT in patients with metastatic castration-resistant prostate cancer treated with [177Lu]Lu-PSMA-617. Methods: In this multicenter retrospective study, the as...
Associations of [18F]PI-2620 Binding with Memory and Phosphorylated Tau 217 in Cognitively Unimpaired Older Adults [0.03%]
[18F]PI-2620 结合与认知功能正常的老年人的记忆和磷酸化 tau 217 的相关性研究
Anne Maass,Berta Garcia-Garcia,Niklas Behrenbruch et al.
Anne Maass et al.
[18F]PI-2620 is a second-generation tau PET tracer that may detect early tau accumulation in aging. We investigated whether temporal lobe [18F]PI-2620 binding is associated with age, sex, genetic Alzheimer disease (AD) risk, plasma biomarke...
An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the Role of the Prostate Cancer Foundation and Cancer Treatment [0.03%]
免疫学家谈如何推动前列腺癌基金会的科学使命：安德里亚·宫城与约翰内斯·岑恩关于前列腺癌基金会的作用及癌症治疗的对话
Andrea Miyahira,Johannes Czernin
Andrea Miyahira
From Ostrich to Mouse to Human: Translation of the Functional Liver PET Tracer [68Ga]Ga-TEoS-DAZA [0.03%]
从鸵鸟到小鼠再到人类：肝脏功能PET显像剂[68Ga]Ga-TEOs-DAZA的翻译研究
Julia Greiser,Robert Drescher,Mitali Sonawane et al.
Julia Greiser et al.
The aim of this study was to investigate the dynamic biodistribution of [68Ga]Ga-TEoS-DAZA, a functional liver PET tracer, in 2 preclinical models (ostrich embryos and mice) and in a healthy human liver donor to identify similarities and di...
Overall Survival with [177Lu]Lu-PSMA-617 Versus [177Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis [0.03%]
[177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA I& T的总生存期：基于倾向性评分匹配的真实世界分析
Natalie Hasenauer,Charlotte Probst,Wiebke Schloetelburg et al.
Natalie Hasenauer et al.
In this study, we compared clinical outcomes and safety profiles of radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer under real-world conditions. Met...
Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined 18F-Flotufolastat PSMA PET and mpMRI [0.03%]
无活检前列腺癌诊断的前景：结合18F-Flotufolastat PSMA PET和mpMRI的潜力
Türkay Hekimsoy,Andreas P Sauter,Robert Tauber et al.
Türkay Hekimsoy et al.
This retrospective analysis aimed to evaluate the diagnostic performance of 18F-flotufolastat PET/MRI for the detection of clinically significant prostate cancer (csPCa). The primary objective of the study was to assess the proportion of pa...
PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study [0.03%]
负向或可疑的多参数磁共振成像男性患者进行PSMA-PET/CT靶向活检：FUPERMAN研究探索性全身动态PET检查结果分析
Andrea Farolfi,Caterina Maria Paola Sgro,Irene Brusa et al.
Andrea Farolfi et al.
Prostate-specific membrane antigen (PSMA) PET/CT may enhance detection of clinically significant prostate cancer (csPCa) in men with negative or equivocal multiparametric MRI (mpMRI), a setting where diagnostic uncertainty persists. This st...
CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment [0.03%]
癌症 CAR-T 细胞治疗：疗效评估的最新研究和挑战
Dorine de Jong,Jeremy P McGale,Timothy J Robinson et al.
Dorine de Jong et al.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for multiple hematologic malignancies, demonstrating a clear curative potential in select cases. Since 2017, 7 CAR T-cell products have indications ap...